Comparison of treatment adherence between selective serotonin reuptake inhibitors and moclobemide in patients with social anxiety disorder

Psychiatry Investigation

Volumn 9, Issue 1, 2012, Pages 73-79

  Lim, Se Won ^a   Kwon, Yong Seok ^a   Ha, Juwon ^a   Yoon, Hyeng Geun ^a   Bae, Seung Min ^b   Shin, Dong Won ^a   Shin, Young Chul ^a   Oh, Kang Seob ^a  

^a School of Medicine   (South Korea)

^b Gachon University   (South Korea)

Author keywords

All cause discontinuation; Moclobemide; Social anxiety disorder; SSRI; Treatment adherence

Indexed keywords

BENZODIAZEPINE DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; ESCITALOPRAM; MOCLOBEMIDE; SEROTONIN UPTAKE INHIBITOR;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL PRACTICE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HUMAN; LIFE EVENT; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; SOCIAL PHOBIA; SURVIVAL RATE; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 84857961444     PISSN: 17383684     EISSN: 19763026     Source Type: Journal    
DOI: 10.4306/pi.2012.9.1.73     Document Type: Article

References (42)

1. Stein DJ, Stein MB, Pitts CD, Kumar R, Hunter B. Predictors of response to pharmacotherapy in social anxiety disorder: an analysis of 3 placebo-controlled paroxetine trials. J Clin Psychiatry 2002;63:152-155.
2. Wittchen HU, Beloch E. The impact of social phobia on quality of life. Int Clin Psychopharmacol 1996;11(Suppl 3):15-23.
3. Kessler RC, Stein MB, Berglund P. Social phobia subtypes in the National Comorbidity Survey. Am J Psychiatry 1998;155:613-619.
4. Brunello N, den Boer JA, Judd LL, Kasper S, Kelsey JE, Lader M, et al. Social phobia: diagnosis and epidemiology, neurobiology and pharmacology, comorbidity and treatment. J Affect Disord 2000;60:61-74.
5. Schneier FR, Johnson J, Hornig CD, Liebowitz MR, Weissman MM. Social phobia. Comorbidity and morbidity in an epidemiologic sample. Arch Gen Psychiatry 1992;49:282-288.
6. Liebowitz MR, Schneier F, Campeas R, Hollander E, Hatterer J, Fyer A, et al. Phenelzine vs atenolol in social phobia. A placebo-controlled comparison. Arch Gen Psychiatry 1992;49:290-300.
7. Schneier FR. Treatment of social phobia with antidepressants. J Clin Psychiatry 2001;62(Suppl 1):43-48.
8. Versiani M, Nardi AE, Mundim FD, Alves AB, Liebowitz MR, Amrein R. Pharmacotherapy of social phobia. A controlled study with moclobemide and phenelzine. Br J Psychiatry 1992;161:353-360.
9. Blanco C, Raza MS, Schneier FR, Liebowitz MR. The evidence-based pharmacological treatment of social anxiety disorder. Int J Neuropsychopharmacol 2003;6:427-442.
10. Versiani M, Nardi AE, Mundim FD, Pinto S, Saboya E, Kovacs R. The long-term treatment of social phobia with moclobemide. Int Clin Psychopharmacol 1996;11(Suppl 3):83-88.
11. Noyes R Jr, Moroz G, Davidson JR, Liebowitz MR, Davidson A, Siegel J, et al. Moclobemide in social phobia: a controlled dose-response trial. J Clin Psychopharmacol 1997;17:247-254.
12. Schneier FR, Goetz D, Campeas R, Fallon B, Marshall R, Liebowitz MR. Placebo-controlled trial of moclobemide in social phobia. Br J Psychiatry 1998;172:70-77.
13. Stein MB, Chartier MJ, Hazen AL, Kroft CD, Chale RA, Cote D, et al. Paroxetine in the treatment of generalized social phobia: open-label treatment and double-blind placebo-controlled discontinuation. J Clin Psychopharmacol 1996;16:218-222.
14. Van Ameringen M, Mancini C, Streiner DL. Fluoxetine efficacy in social phobia. J Clin Psychiatry 1993;54:27-32.
15. Bouwer C, Stein DJ. Use of the selective serotonin reuptake inhibitor citalopram in the treatment of generalized social phobia. J Affect Disord 1998;49:79-82.
16. Atmaca M, Kuloglu M, Tezcan E, Unal A. Efficacy of citalopram and moclobemide in patients with social phobia: some preliminary findings. Hum Psychopharmacol 2002;17:401-405.
17. Ackerman DL, Greenland S, Bystritsky A, Morgenstern H, Katz RJ. Predictors of treatment response in obsessive-compulsive disorder: multivariate analyses from a multicenter trial of clomipramine. J Clin Psychopharmacol 1994;14:247-254.
18. Davidson JR, Kudler HS, Saunders WB, Erickson L, Smith RD, Stein RM, et al. Predicting response to amitriptyline in posttraumatic stress disorder. Am J Psychiatry 1993;150:1024-1029.
19. Lader M, Stender K, Burger V, Nil R. Efficacy and tolerability of escitalopram in 12-and 24-week treatment of social anxiety disorder: randomised, double-blind, placebo-controlled, fixed-dose study. Depress Anxiety 2004;19:241-248.
20. Versiani M, Amrein R, Montgomery SA. Social phobia: long-term treatment outcome and prediction of response--a moclobemide study. Int Clin Psychopharmacol 1997;12:239-254.
21. Stein MB, Cantrell CR, Sokol MC, Eaddy MT, Shah MB. Antidepressant adherence and medical resource use among managed care patients with anxiety disorders. Psychiatr Serv 2006;57:673-680.
22. Yamada M, Yasuhara H. Clinical pharmacology of MAO inhibitors: safety and future. Neurotoxicology 2004;25:215-221.
23. Volz HP, Gleiter CH. Monoamine oxidase inhibitors. A perspective on their use in the elderly. Drugs Aging 1998;13:341-355.
24. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC: American Psychiatric Press; 1994.
25. Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998;59(Suppl 20):22-33.
26. Stroup TS, McEvoy JP, Swartz MS, Byerly MJ, Glick ID, Canive JM, et al. The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development. Schizophr Bull 2003;29:15-31.
27. Weiden PJ. Discontinuing and switching antipsychotic medications: understanding the CATIE schizophrenia trial. J Clin Psychiatry 2007; 68(Suppl 1):12-19.
28. Cox D, Oakes D. Analysis of Survival Data. London: Chapman and Hall; 1984.
29. Cox D. Regression models and life tables. J R Stat Soc B 1972;34:187-220.
30. Edlund MJ, Wang PS, Berglund PA, Katz SJ, Lin E, Kessler RC. Dropping out of mental health treatment: patterns and predictors among epidemiological survey respondents in the United States and Ontario. Am J Psychiatry 2002;159:845-851.
31. Sonawalla SB, Farabaugh AH, Leslie VM, Pava JA, Matthews JD, Fava M. Early drop-outs, late drop-outs and completers: differences in the continuation phase of a clinical trial. Prog Neuropsychopharmacol Biol Psychiatry 2002;26:1415-1419.
32. Linden M, Osterheider M, Nickelsen T, Schaaf B. Three types of early termination of antidepressant drug treatment. Int Clin Psychopharmacol 1993;8:345-346.
33. Velligan DI, Wang M, Diamond P, Glahn DC, Castillo D, Bendle S, et al. Relationships among subjective and objective measures of adherence to oral antipsychotic medications. Psychiatr Serv 2007;58:1187-1192.
34. Wong JL. Lay theories of psychotherapy and perceptions of therapists: a replication and extension of Furnham and Wardley. J Clin Psychol 1994;50:624-632.
35. Howard KI, Cornille TA, Lyons JS, Vessey JT, Lueger RJ, Saunders SM. Patterns of mental health service utilization. Arch Gen Psychiatry 1996;53:696-703.
36. Weinick RM, Byron SC, Bierman AS. Who can't pay for health care? J Gen Intern Med 2005;20:504-509.
37. Olfson M, Mojtabai R, Sampson NA, Hwang I, Druss B, Wang PS, et al. Dropout from outpatient mental health care in the United States. Psychiatr Serv 2009;60:898-907.
38. Ravindran LN, Stein MB. The pharmacologic treatment of anxiety disorders: a review of progress. J Clin Psychiatry 2010;71:839-854.
39. Stangier U, Schramm E, Heidenreich T, Berger M, Clark DM. Cognitive therapy vs interpersonal psychotherapy in social anxiety disorder: a randomized controlled trial. Arch Gen Psychiatry 2011;68:692-700.
40. Mullins CD, Shaya FT, Meng F, Wang J, Harrison D. Persistence, switching, and discontinuation rates among patients receiving sertraline, paroxetine, and citalopram. Pharmacotherapy 2005;25:660-667.
41. Rickles NM, Svarstad BL. Relationships between multiple self-reported nonadherence measures and pharmacy records. Res Social Adm Pharm 2007;3:363-377.
42. Andersen RM. Revisiting the behavioral model and access to medical care: does it matter? J Health Soc Behav 1995;36:1-10.